Bianchi C, Donadio C, Tramonti G, Lorusso P, Bellitto L, Lunghi F
Eur J Nucl Med. 1984;9(6):257-60. doi: 10.1007/BF00803246.
Aprotinin (Ap), a low-molecular-weight polypeptide (6500 dalton), is a protease inhibitor which is electively and stably accumulated in the kidney. In 112 adult patients, with either uni- or bilateral renal disease with different degrees of renal impairment (from normal GFR to advanced renal failure), renal scans were performed by means of Ap labelled with 99mTc. Highly satisfactory renal scans were obtained in all patients. In 20 patients with renal failure (serum creatinine 1.8-8.5 mg/dl, mean 4.7) a comparison was made of the renal scans obtained with 99mTc-Ap and with 99mTc-DMSA. 99mTc-Ap was slightly better than 99mTc-DMSA, especially in patients with far advanced renal failure. Some aspects of the pharmacokinetics of 99mTc-Ap were studied in 72 cases. In 22 of these patients plasma clearance of 99mTc-Ap was determined by the single injection method using a two-compartment model. In patients with GFR greater than 90 ml/min plasma clearance of 99mTc-Ap was 67.6 +/- 8.4 SD ml/min. A good correlation was observed between plasma clearance of 99mTc-Ap and GFR (r = 0.74). After IV injection 99mTc-Ap was stably fixed by the kidney. Renal radioactivity remained stable between the second and eighth hour after the injection. Urinary excretion of radioactivity measured in 35 patients in the first and in the second 2-h interval after IV injection of 99mTc-Ap was negligible in all patients (2.7 +/- 1.5 SD percent of the dose in the first 2 h; 2.8 +/- 1.4 SD between the second and fourth hour). 99mTc-Ap is an excellent agent for renal imaging. It also seems promising for renal function studies.
抑肽酶(Ap)是一种低分子量多肽(6500道尔顿),是一种蛋白酶抑制剂,可选择性且稳定地蓄积于肾脏。在112例患有单侧或双侧肾脏疾病且肾功能损害程度不同(从正常肾小球滤过率到晚期肾衰竭)的成年患者中,通过用99mTc标记的Ap进行肾脏扫描。所有患者均获得了高度满意的肾脏扫描结果。在20例肾衰竭患者(血清肌酐1.8 - 8.5mg/dl,平均4.7)中,对用99mTc - Ap和99mTc - DMSA获得的肾脏扫描结果进行了比较。99mTc - Ap略优于99mTc - DMSA,尤其是在晚期肾衰竭患者中。在72例患者中研究了99mTc - Ap的一些药代动力学方面。在其中22例患者中,采用二室模型通过单次注射法测定了99mTc - Ap的血浆清除率。在肾小球滤过率大于90ml/min的患者中,99mTc - Ap的血浆清除率为67.6±8.4标准差ml/min。观察到99mTc - Ap的血浆清除率与肾小球滤过率之间存在良好的相关性(r = 0.74)。静脉注射后,99mTc - Ap被肾脏稳定摄取。注射后第二至第八小时肾脏放射性保持稳定。在静脉注射99mTc - Ap后的第一个和第二个2小时间隔内,对35例患者测量的放射性尿液排泄在所有患者中均可忽略不计(第一个2小时内为剂量的2.7±1.5标准差百分比;第二个和第四个小时之间为2.8±1.4标准差)。99mTc - Ap是一种用于肾脏成像的优秀试剂。它在肾功能研究方面似乎也很有前景。